Biological trace element research · 2025
Serum Copper Levels in Chronic Kidney Disease and Hemodialysis Patients: Insights from a Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aldalati Abdullah Yousef, Hussein Ayham Mohammad, Balbaa Elsayed, Alrabadi Bassel, Albliwi Moath, Abuassi Mohammad, Rawashdeh Badi
Аннотация
BACKGROUND: Copper is an essential trace element involved in numerous enzymatic functions and physiological processes. Chronic kidney disease (CKD) and hemodialysis (HD) may influence copper homeostasis, yet conflicting findings exist regarding copper levels in these patients and copper levels aren't routinely checked. This systematic review and meta-analysis evaluates serum copper concentrations in CKD and HD patients compared to healthy controls (HC), and assesses changes pre- and post-HD.
METHODS: A systematic search of PubMed, Scopus, Cochrane Library, EMBASE, and Web of Science was conducted up to February 2025. Observational studies reporting serum copper levels in CKD and HD patients were included. Data analysis were conducted using RevMan software. The data were pooled as standardized mean difference (SMD) and using a random-effects model.
RESULTS: A total of 42 studies with 13,592 participants were included. No significant difference in copper levels was observed between CKD patients and HC (SMD: -0.18, 95% CI: -1.17, 0.80; P = 0.71). However, HD patients had significantly lower copper levels compared to HC (SMD: -0.48, 95% CI: -0.89, -0.07; P = 0.02). Additionally, HD significantly reduced serum copper levels post-treatment compared to pre-HD (SMD: -0.41, 95% CI: -0.62, -0.21; P < 0.0001).
CONCLUSION: Our findings suggest that CKD does not significantly impact serum copper levels, whereas HD leads to a significant decrease in copper concentrations. The mechanisms underlying this reduction require further elucidation, and future studies should explore the potential clinical consequences of low copper levels in HD patients.
METHODS: A systematic search of PubMed, Scopus, Cochrane Library, EMBASE, and Web of Science was conducted up to February 2025. Observational studies reporting serum copper levels in CKD and HD patients were included. Data analysis were conducted using RevMan software. The data were pooled as standardized mean difference (SMD) and using a random-effects model.
RESULTS: A total of 42 studies with 13,592 participants were included. No significant difference in copper levels was observed between CKD patients and HC (SMD: -0.18, 95% CI: -1.17, 0.80; P = 0.71). However, HD patients had significantly lower copper levels compared to HC (SMD: -0.48, 95% CI: -0.89, -0.07; P = 0.02). Additionally, HD significantly reduced serum copper levels post-treatment compared to pre-HD (SMD: -0.41, 95% CI: -0.62, -0.21; P < 0.0001).
CONCLUSION: Our findings suggest that CKD does not significantly impact serum copper levels, whereas HD leads to a significant decrease in copper concentrations. The mechanisms underlying this reduction require further elucidation, and future studies should explore the potential clinical consequences of low copper levels in HD patients.